Drug Combination Details
| General Information of the Combination (ID: C72558) | |||||
|---|---|---|---|---|---|
| Name | Bisdemethoxycurcumin NP Info | + | X-ray irradiation Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Anaplastic large cell lymphoma
[ICD-11: 2A90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
BDMC stimulates the dephosphorylation and p53-binding activity of Bcl-2 and suggest that BDMC may induce a neutralization of Bcl-2's anti-apoptotic function, thereby enhancing X-ray-induced apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Bisdemethoxycurcumin enhances X-ray-induced apoptosis possibly through p53/Bcl-2 pathway. Mutat Res. 2017 Mar;815:1-5. | |||
